secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000926617-23-000093
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health Q3 product revenue up 9% to $2.2M; cash burn down 56% to $3.3M
--------------------------------------------------------------------------------

- Product revenue $2.2M (+9% YoY); OvaSuite volume 5,783 units (+5% YoY).
- OvaWatch tests reached 1,015 in Q3, now nearly 20% of total OvaSuite volume.
- Cash used in operations $3.3M, down 56% from $7.5M in Q3 2022; reiterated H2 2023 target $6-8M.
- Gross margin improved to 59.0% from 55.8% YoY; R&D and SG&A expenses each down >50% YoY.
- Raised $4.7M gross proceeds in registered direct offering; total cash $5.4M at Sep 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/0000926617-23-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/awh-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0000926617-23-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer